Special drugs for lung cancer: Is mobosetinib/mobosetinib a targeted drug? Belong to several generations

Mobocertinib/Mobocertinib(Mobocertinib) is a third-generation targeted drug. Targeted drugs are usually classified based on their mechanism of action and structural characteristics of tumor cells. Mobosetinib is an irreversible small molecule EGFR TKI specifically designed to selectively target EGFR exon 20 insertion mutants. It is the world's first and currently only approved oral targeted drug for the treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mutations (EGFRexon20Insertion+).

The first generation of targeted drugs mainly include gemcitabine (Gefitinib), Erlotinib, etc.; the second generation of targeted drugs mainly include afatinib (Afatinib), dacomitinib (Dacomitinib), etc.; and the third generation of targeted drugs refers to a new generation of drugs that provide better therapeutic effects for non-small cell lung cancer with EGFR gene mutations, of which mobosetinib is one of the newly developed third generation targeted drugs. These drugs are developed to improve efficacy and reduce side effects, providing patients with better treatment options.

Mobosetinib The original drug has been launched in China, but it is not included in the medical insurance. The price of the common specification 40mg*112 pills per box is about 40,000 yuan, which is very high. The Hong Kong clinical version specification 40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.